ArticleBioMed research international2026
Integrons and Efflux Pump-Mediated Antibiotic Resistance in Multidrug-Resistant (MDR) Uropathogenic Escherichia coli.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Synergistic Effects of Amikacin With Imipenem and Ciprofloxacin Against Multidrug-Resistance UropathogenicThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Integrons and Efflux Pump-Mediated Antibiotic Resistance in Multidrug-Resistant (MDR) Uropathogenic Escherichia coli.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIntegrons facilitate the acquisition and expression of antibiotic resistance genes, with Classes 1 and 2 commonly found in clinical E. coli. The AcrAB-TolC efflux pump is a major RND system that expels diverse antimicrobial agents and contributes to resistance. This study is aimed at determining the prevalence of Class 1/2 integrons and the AcrAB-TolC efflux pump in UPEC isolates from UTI patients in Babol, Iran.
methodsThis cross-sectional study analyzed 155 UPEC isolates collected from UTI patients in Babol, northern Iran (2021-2023). Isolates were identified using standard biochemical and genotypic methods. Antimicrobial susceptibility was assessed by disk diffusion. Polymerase chain reaction (PCR) was used to detect the presence of integron and efflux pump genes. Statistical analysis was performed using SPSS (Version 16), with significance defined at p value < 0.05.
resultsFindings revealed that 85.2% of the isolates carried Class 1 integrons, whereas 23.2% contained Class 2 integrons. Integron-positive isolates presented an increased level of antibiotic resistance, particularly to trimethoprim-sulfamethoxazole (75% and 88.9%) and nalidixic acid (90.9% and 91.7%). Additionally, over 88% of the isolates had AcrAB-TolC efflux pump genes. MDR rates were 75% among intI1-positive isolates and 83.3% among intI2-positive isolates.
conclusionIn conclusion, integrons contribute to the spread of antibiotic resistance among UPEC isolates, whereas the AcrAB-TolC efflux pump contributes to the ability of bacteria to expel toxic substances. There is a need for effective infection management policies and proper application of antibiotics to limit the dissemination of resistance genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.